$TOVX
Theriva Biologics, Inc. Stock $tovx

$tovx Overview Financials Valuation SEC Filings Company Website

2017 Form 10-K Financial Statement

#000114420418010286 Filed on February 22, 2018

Income Statement

Concept	2017	2016 Q4	2016 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.467M	$3.480M	$2.100M
YoY Change	-26.38%	37.01%	31.25%
% of Gross Profit
Research & Development	$18.78M	$6.730M	$7.061M
YoY Change	-35.47%	-24.04%	-29.71%
% of Gross Profit
Depreciation & Amortization	$245.0K	$50.00K	$50.00K
YoY Change	56.05%	66.67%	150.0%
% of Gross Profit
Operating Expenses	$26.25M	$10.20M	$9.156M
YoY Change	-33.12%	-10.45%	-21.41%
Operating Profit	-$26.25M		-$9.156M
YoY Change	-33.12%		-21.41%
Interest Expense	$21.00K	$0.00	$0.00
YoY Change	-43.24%
% of Operating Profit
Other Income/Expense, Net	$10.76M	$7.730M	$667.0K
YoY Change	-6.03%	7630.0%	-83.9%
Pretax Income	-$15.49M	-$10.20M	-$9.156M
YoY Change	-44.28%	-10.44%	-21.41%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$15.17M	-$2.472M	-$8.489M
YoY Change	-44.33%	-78.12%	13.08%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.02	-$0.09
Diluted Earnings Per Share	-$42.71M	-$0.02	-$0.09
COMMON SHARES
Basic Shares Outstanding		103.8M shares	91.44M shares
Diluted Shares Outstanding		103.8M shares	91.44M shares

Balance Sheet

Concept	2017	2016 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.12M	$19.06M	$4.550M
YoY Change	-10.18%	-8.45%	-85.7%
Cash & Equivalents	$17.12M	$19.06M	$4.549M
Short-Term Investments
Other Short-Term Assets	$827.0K	$185.0K	$294.0K
YoY Change	-67.12%		-97.15%
Inventory
Prepaid Expenses		$295.0K
Receivables
Other Receivables		$0.00
Total Short-Term Assets	$17.94M	$21.57M	$7.640M
YoY Change	-16.82%	-28.9%	-81.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$872.0K	$905.0K	$580.0K
YoY Change	-3.65%	83.2%	20.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$23.00K	$20.00K	$30.00K
YoY Change	0.0%	100.0%	200.0%
Total Long-Term Assets	$895.0K	$928.0K	$610.0K
YoY Change	-3.56%	80.9%	22.74%
TOTAL ASSETS
Total Short-Term Assets	$17.94M	$21.57M	$7.640M
Total Long-Term Assets	$895.0K	$928.0K	$610.0K
Total Assets	$18.84M	$22.50M	$8.250M
YoY Change	-16.27%	-27.07%	-80.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.020M	$1.993M	$4.240M
YoY Change	1.35%	-54.81%	-29.64%
Accrued Expenses	$3.600M	$2.627M	$2.830M
YoY Change	22.45%	784.51%	1059.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.793M	$19.76M	$14.01M
YoY Change	-50.43%	26.85%	-19.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$402.0K	$490.0K	$210.0K
YoY Change	-18.29%	81.48%	5.0%
Total Long-Term Liabilities	$402.0K	$490.0K	$210.0K
YoY Change	-18.29%	81.48%	5.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.793M	$19.76M	$14.01M
Total Long-Term Liabilities	$402.0K	$490.0K	$210.0K
Total Liabilities	$8.281M	$20.25M	$12.72M
YoY Change	-55.6%	27.82%	-27.31%
SHAREHOLDERS EQUITY
Retained Earnings		-$172.0M
YoY Change
Common Stock		$175.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.56M	$3.845M	-$4.480M
YoY Change
Total Liabilities & Shareholders Equity	$18.84M	$22.50M	$8.250M
YoY Change	-16.27%	-27.07%	-80.65%

Cashflow Statement

Concept	2017	2016 Q4	2016 Q3
OPERATING ACTIVITIES
Net Income	-$15.17M	-$2.472M	-$8.489M
YoY Change	-44.33%	-78.12%	13.08%
Depreciation, Depletion And Amortization	$245.0K	$50.00K	$50.00K
YoY Change	56.05%	66.67%	150.0%
Cash From Operating Activities	-$20.20M	-$10.38M	-$5.990M
YoY Change	-27.59%	-5.38%	-60.62%
INVESTING ACTIVITIES
Capital Expenditures	$212.0K	-$370.0K	-$150.0K
YoY Change	-62.74%	825.0%	-62.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$212.0K	-$370.0K	-$150.0K
YoY Change	-62.74%	825.0%	-62.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$300.0K
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	18.48M	25.26M	640.0K
YoY Change	-30.82%	126200.0%	-98.5%
NET CHANGE
Cash From Operating Activities	-20.20M	-10.38M	-5.990M
Cash From Investing Activities	-212.0K	-370.0K	-150.0K
Cash From Financing Activities	18.48M	25.26M	640.0K
Net Change In Cash	-1.939M	14.51M	-5.500M
YoY Change	9.98%	-232.03%	-120.33%
FREE CASH FLOW
Cash From Operating Activities	-$20.20M	-$10.38M	-$5.990M
Capital Expenditures	$212.0K	-$370.0K	-$150.0K
Free Cash Flow	-$20.42M	-$10.01M	-$5.840M
YoY Change	-28.29%	-8.42%	-60.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46000000	USD
CY2016Q4	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	2211000	USD
CY2017Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	661000	USD
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	64400000	USD
CY2017	dei	Trading Symbol TradingSymbol	SYN
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	128566886	shares
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19055000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2515000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	21570000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	905000	USD
CY2016Q4	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	23000	USD
CY2016Q4	us-gaap	Assets Assets	22498000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1993000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2627000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19757000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	20249000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	129000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	117000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	192545000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	175762000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-194170000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-172034000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-1496000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	3845000	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	-1914000	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	-1596000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3410000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2249000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18838000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22498000	USD
CY2017Q4	syn	Warrant Liabilities WarrantLiabilities	4083000	USD
CY2016Q4	syn	Warrant Liabilities WarrantLiabilities	14821000	USD
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2074000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	313000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	90000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	3000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	402000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	492000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	39252000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-39252000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	37000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11449000	USD
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-548000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-27255000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-11412000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8074000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-40980000	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1048000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-43737000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2017	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6962000	USD
CY2016	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2015	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22136000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27255000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-43737000	USD
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	124366059	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	94290436	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80705692	shares
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	4009000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7004000	USD
CY2016	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	9000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2420000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2330000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27901000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	569000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26707000	USD
CY2016	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-1763000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20818000	USD
CY2016	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	207000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	3409000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1688000	USD
CY2017	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	0	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	27000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20204000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	212000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-212000	USD
CY2017	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	166000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18477000	USD
CY2017	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-1939000	USD
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1761000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1101000	USD
CY2017	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-3000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	157000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	245000	USD
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	6358000	USD
CY2016	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1509000	USD
CY2017	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	11953000	USD
CY2016	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	429000	USD
CY2016Q4	syn	Accrued Vendor Payments AccruedVendorPayments	400000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2000	USD
CY2017	syn	Issue Of Stock For Exclusive Channel Collaboration Agreement IssueOfStockForExclusiveChannelCollaborationAgreement	0	USD
CY2016	syn	Issue Of Stock For Exclusive Channel Collaboration Agreement IssueOfStockForExclusiveChannelCollaborationAgreement	0	USD
CY2015	syn	Issue Of Stock For Exclusive Channel Collaboration Agreement IssueOfStockForExclusiveChannelCollaborationAgreement	-3000000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	72000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7971000	USD
CY2016Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	14000	USD
CY2017	us-gaap	Dividends Preferred Stock DividendsPreferredStock	73000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	3198000	USD
CY2017	syn	Stock Issued For Milestone Payments StockIssuedForMilestonePayments	0	USD
CY2016	syn	Stock Issued For Milestone Payments StockIssuedForMilestonePayments	0	USD
CY2015	syn	Stock Issued For Milestone Payments StockIssuedForMilestonePayments	-1350000	USD
CY2017Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1283000	USD
CY2016Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	0	USD
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	201000	USD
CY2016Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	261000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2074000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	313000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128648365	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117254196	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128566886	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117172714	shares
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9556000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3198000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4009000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3409000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42643000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	24384000	USD
CY2015	syn	Stock Issued During Period Valuemilestone Payment StockIssuedDuringPeriodValuemilestonePayment	1350000	USD
CY2015	syn	Stock Issued During Period Value For Exclusive Channel Collaboration Agreement StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement	3000000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	814000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	166000	USD
CY2015	syn	Issuance Value Of Common Stock Upon Exercise Of Warrants IssuanceValueOfCommonStockUponExerciseOfWarrants	0	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	15667000	USD
CY2016	syn	Stock Issued During Period At Market Offering Value StockIssuedDuringPeriodAtMarketOfferingValue	1509000	USD
CY2017	syn	Stock Issued During Period At Market Offering Value StockIssuedDuringPeriodAtMarketOfferingValue	6358000	USD
CY2017	syn	Adjustments To Additional Paid In Capital Convertible Preferred Stock With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertiblePreferredStockWithConversionFeature	0	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	27000	USD
CY2015	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	8000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3417000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1001000	USD
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-261000	USD
CY2015	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	288000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38890000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	501000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-501000	USD
CY2015	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2015	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	41000	USD
CY2015	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000000	USD
CY2017	syn	Direct Offering Cost DirectOfferingCost	0	USD
CY2016	syn	Direct Offering Cost DirectOfferingCost	616000	USD
CY2015	syn	Direct Offering Cost DirectOfferingCost	3357000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42684000	USD
CY2015	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	3293000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17525000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8149000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6475000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5842000	USD
CY2017Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5783000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-3058000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-4315000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-10930000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	2812000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	117447260	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123005220	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128279674	shares
CY2017Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128566883	shares
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Use of Estimates</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, fair value of warrants, preferred stock and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117447260	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123005220	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128279674	shares
CY2017Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150847262	shares
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90826752	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91015733	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91441687	shares
CY2016Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103804308	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90826752	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93930540	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91441687	shares
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10581000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9311000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9156000	USD
CY2016Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10204000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-11078000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-5764000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-8489000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-2472000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2016Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.885	pure
CY2016Q4	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.115	pure
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-5267000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-9453000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	700000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2200000	USD
CY2017Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	46000	USD
CY2016Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1700000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-613000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-1101000	USD
CY2017	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-2000	USD
CY2016	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-431000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	10000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	10000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	502000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	574000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-4076000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-4332000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	21555000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12109000	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-14733000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q4	syn	Deferred Tax Assets Stocks Issued For Services DeferredTaxAssetsStocksIssuedForServices	1730000	USD
CY2016Q4	syn	Deferred Tax Assets Stocks Issued For Services DeferredTaxAssetsStocksIssuedForServices	1861000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	164000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	119000	USD
CY2017Q4	syn	Deferred Tax Assets Stock Issued For Acquisition Of Program DeferredTaxAssetsStockIssuedForAcquisitionOfProgram	1202000	USD
CY2016Q4	syn	Deferred Tax Assets Stock Issued Forlicense Agreement DeferredTaxAssetsStockIssuedForlicenseAgreement	3147000	USD
CY2017Q4	syn	Deferred Tax Assets Stock Issued For Milestone Payment DeferredTaxAssetsStockIssuedForMilestonePayment	301000	USD
CY2016Q4	syn	Deferred Tax Assets Stock Issued For Milestone Payment DeferredTaxAssetsStockIssuedForMilestonePayment	478000	USD
CY2017Q4	syn	Deferred Tax Assets Tax Deferred Expense Amortizable License Fee DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee	6000	USD
CY2016Q4	syn	Deferred Tax Assets Tax Deferred Expense Amortizable License Fee DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee	9000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40248000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	50517000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45598000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57707000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45598000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57707000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0396	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.3796	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0396	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.3796	pure
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	156400000	USD
CY2017	syn	Operating Loss Carryforwards Expire Date OperatingLossCarryforwardsExpireDate	2037
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	351000	USD
CY2016Q4	us-gaap	Prepaid Insurance PrepaidInsurance	358000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	292000	USD
CY2017Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	290000	USD
CY2016Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	185000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	300000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	94000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	295000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	309000	USD
CY2017Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	46000	USD
CY2016Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	321000	USD
CY2017Q4	syn	Prepaid Clinical Research Organizations Expense Current PrepaidClinicalResearchOrganizationsExpenseCurrent	46000	USD
CY2016Q4	syn	Prepaid Clinical Research Organizations Expense Current PrepaidClinicalResearchOrganizationsExpenseCurrent	1677000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	192000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1414000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1301000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1091000	USD
CY2017Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent	590000	USD
CY2016Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent	52000	USD
CY2017	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	3000000	USD
CY2017Q4	syn	Exchange Percentage Of Unregistered Common Stock ExchangePercentageOfUnregisteredCommonStock	0.5	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2017Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.885	pure
CY2017Q4	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.115	pure
CY2015Q4	syn	Warrant Liabilities WarrantLiabilities	10566000	USD
CY2016	syn	Issuance Of Warrants IssuanceOfWarrants	15667000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7908899	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	50000000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2016	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	0	shares
CY2017	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	0	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	567257	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	25311834	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	57341642	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	32029809	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.60
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.50
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.72
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	2.35
CY2017	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	0
CY2016	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.58
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.79
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2900000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	166000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	814000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	41000	USD
CY2017Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	73000	USD
CY2016Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	23300000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15003000	USD
CY2016Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	300000	USD
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2017	syn	Options To Be Received Common Stock Shares OptionsToBeReceivedCommonStockShares	2000000	shares
CY2016	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	643000	USD
CY2015	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	424000	USD
CY2017	us-gaap	Line Of Credit Facility Periodic Payment Interest LineOfCreditFacilityPeriodicPaymentInterest	381150	USD
CY2012Q1	us-gaap	Officers Compensation OfficersCompensation	348000	USD
CY2014Q2	us-gaap	Officers Compensation OfficersCompensation	385000	USD
CY2015	us-gaap	Officers Compensation OfficersCompensation	385000	USD
CY2016Q4	syn	Operating Annual Lease Payments OperatingAnnualLeasePayments	285843	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	199000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	145000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	108000	USD
CY2017Q4	us-gaap	Payments For Fees PaymentsForFees	5500000	USD
CY2016	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	3000000	USD
CY2017Q4	us-gaap	Share Price SharePrice	0.51
CY2016Q4	us-gaap	Share Price SharePrice	0.76
CY2016Q4	us-gaap	Share Price SharePrice	1.75
CY2017	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2016	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q4	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2017	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.8	pure
CY2016	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2016Q4	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2017	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0186	pure
CY2016	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0141	pure
CY2016Q4	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0139	pure
CY2017	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y9M14D
CY2016	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P2Y9M14D
CY2016Q4	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure

Files In Submission

Name	View Source	Status
0001144204-18-010286-index-headers.html	Edgar Link	pending
0001144204-18-010286-index.html	Edgar Link	pending
0001144204-18-010286.txt	Edgar Link	pending
0001144204-18-010286-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
syn-20171231.xml	Edgar Link	completed
syn-20171231.xsd	Edgar Link	pending
syn-20171231_cal.xml	Edgar Link	unprocessable
syn-20171231_def.xml	Edgar Link	unprocessable
syn-20171231_lab.xml	Edgar Link	unprocessable
syn-20171231_pre.xml	Edgar Link	unprocessable
tv485536_10k.htm	Edgar Link	pending
tv485536_ex10-53.htm	Edgar Link	pending
tv485536_ex10-54.htm	Edgar Link	pending
tv485536_ex21.htm	Edgar Link	pending
tv485536_ex23-1.htm	Edgar Link	pending
tv485536_ex31-1.htm	Edgar Link	pending
tv485536_ex32-1.htm	Edgar Link	pending
tv485536_img1.jpg	Edgar Link	pending
tv485536_img2.jpg	Edgar Link	pending
tv485536_img3.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TOVX
Theriva Biologics, Inc. Stock $tovx

2017 Form 10-K Financial Statement

#000114420418010286 Filed on February 22, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX Theriva Biologics, Inc. Stock $tovx

2017 Form 10-K Financial Statement

#000114420418010286 Filed on February 22, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX
Theriva Biologics, Inc. Stock $tovx